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2072Objective: Decision making regarding the management of the ascending aorta (AA) in patients with a bicuspid
aortic valve (BAV) undergoing valve surgery has hardly been individualized and remains controversial. We
analyzed our individualized, multifactorial approach, focusing on the BAV phenotype.
Methods: In 1362 patients (1044 men) undergoing aortic valve surgery, the BAV phenotypes were intraopera-
tively classified and retrospectively analyzed. The mean follow-up was 5.4  3.6 years (range, 0-14; 7334
patient-years), and the data were 96.5% complete. The individualized AAmanagement decision process mainly
included the AA diameter, age, body surface area, macroscopic AA configuration, and the perceived tissue
strength of the aortic wall resulting in 3 AA treatment groups: no intervention, aortoplasty (AoP), and AA
replacement (AAR).
Results: In 906 patients (66.5%), no intervention was performed and 172 (12.6%) and 284 (20.9%) underwent
AoP and AAR, respectively. The hospital mortality was 1.1% for no intervention, 0.6% for AoP, and 0.4% for
AAR (P¼ .4). The 10-year survival was similar for all 3 groups and comparable to that of the general population.
Five reoperations on the AA occurred, 4 in the no intervention and 1 in the AoP group. BAV type 2/unicuspid
patients were younger and more had undergone AAR in absolute numbers and after allowing for the AA diam-
eter. Also, in patients with BAV type 1 LR and regurgitation, AAR was performed more often.
Conclusions: The individualized, multifactorial management of AA in patients with BAV during aortic valve
surgery leads to excellent results. The threshold AA diameter for intervention (AoP or AAR) varied from 34
to 51 mm (mean, 43.9). BAV type 2/unicuspid and BAV type 1 LR with regurgitation emerged as determinants
for more liberal AAR in our practice. Longer term follow-up is necessary to confirm our conclusions. (J Thorac
Cardiovasc Surg 2014;148:2072-80)See related commentary on pages 2080-1.Supplemental material is available online.
Increasing research on bicuspid aortic valve (BAV) disease
during the past decade has underscored its increasing
importance as the most frequent congenital malformation.
It has a 1% to 2% incidence in the general population,
imposing a considerable health burden.1 Not only thee Department of Cardiac and Thoracic Vascular Surgery, University of
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The Journal of Thoracic and Cardiovascular Survalvulopathy, but especially the BAV-associated aortopathy,
has attracted clinical and scientific attention. A 6- to 9-fold
increased risk of aortic complications such as rupture and
dissection in patients with BAV compared with the general
population has been reported.2-4 Therefore, it is of
significant therapeutic relevance to investigate how to
treat the dilated ascending aorta (AA) at valve surgery.
Previously, the decision has mainly been determined by
the AA diameter. It has been well accepted that AA
replacement (AAR) is indicated for larger diameters.
However, considerable debate has ensued on how to treat
patients with a smaller AA diameter.E1,5,6 Recently, a
large survey uncovered large gaps in knowledge and
attitudes among surgeons regarding how to treat BAV
aortopathy.5 In addition to the diameter of the AA,
additional factors such as the quality or pathologic features
of the aortic wall could be associated with the risk of AA
complications. Several reports have showed that the
histologic features of the AAwall in BAVwill not be normal
and might be related to genetic abnormalities.3,7 However,
some evidence has shown that hemodynamics play a role
in the dilatation process.8,9 It is probable that both
genetics and hemodynamics are important interactinggery c November 2014
Abbreviations and Acronyms
AA ¼ ascending aorta
AoP ¼ aortoplasty
BAV ¼ bicuspid aortic valve
BSA ¼ body surface area
LR ¼ raphe between left coronary and right
coronary sinuses
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various phenotypes of the BAV could be associated with
AA dilatation. To answer the question of whether the
phenotypes of BAV could serve as determinants for decision
making, we analyzed our management protocol of the
AA during valve surgery in 1362 patients with BAV with
a special focus on the BAV phenotypes.METHODS
Patients
A total of 1663 patients with BAV and without associated genetic syn-
dromes (eg, Marfan, Loeys-Dietz, transforming growth factor-b receptor
1 or 2 mutation, Turner) underwent cardiac surgery from February 1999
to April 2013. A total of 1476 consecutive patients with BAVs (88.8%)
were classified during surgery. The missing classifications occurred
because during our initial experience, the presence of BAV was recorded
but we had no awareness to differentiate the phenotype. We excluded 15
patients with acute type A dissection, 30 patients with endocarditis, and
9 patients who did not undergo valve surgery. Also, 60 patients were
excluded because of previous cardiac surgery. The final sample size con-
sisted of 1362 patients with intraoperatively classified BAVs. The patient
characteristics, valve procedures, pre- and intraoperative data, and BAV
phenotypes are listed in Table 1. The follow-up data for these 1362 patients
were 96.5% complete. The follow-up period ranged from 0 to 14 years
(mean, 5.4  3.6), with a cumulative follow-up duration of 7334
patient-years (no intervention, 4880 patient-years, 96.6% complete;
aortoplasty [AoP], 1012 patient-years, 98.3% complete; AAR, 1441
patient-years, 95.4% complete). The follow-up protocol consisted of
outpatient visits and written questionnaires to the family doctor. The local
ethics committee of the University of L€ubeck approved the present study.
BAV Classification
BAVis a collective term for aortic valveswith the characteristic oval, fish
mouth-like orifice but with different phenotypes. Classification of the BAV
phenotype is necessary to evaluate the phenotype-related effects and is sine
qua non for accurate scientific communication. Our classification of the
BAV is a raphe- or fusion-related description.10 In brief, the classification
system was based on macroscopic observation during valve surgery. The
resulting nomenclature is intuitive and self-explanatory, covering thewhole
spectrum of phenotypes of the BAV complex.10 The so-called unicuspid
valve has been included in the BAV classification system as BAV type
2,10 because it also presents with the typical fishmouth-like bifoliate orifice
and has raphes and developed and underdeveloped commissures, in princi-
ple similar to the morphologic characteristics of the classic BAV type 1.
Other investigators have also supported the concept that the unicuspid valve
shares many features of the classic BAV.11 To underline this connection, the
term ‘‘unicuspid’’ has now been added to BAV type 2, reading BAV type
2/unicuspid. Only the most frequently observed types of BAV are shown
in Figure 1; however, Tables 1 and E1 include all recorded BAV types.The Journal of Thoracic and CarHemodynamics, Indication for Surgery and
Diameter Measurement
Preoperatively, the pressure gradient across the aortic valve
was measured using angiocardiography or echocardiography. Aortic
insufficiency was assessed using color flow Doppler techniques and graded
by the jet height in relation to the left ventricular outflow tract height.10 The
indications for surgery were according to the American College of
Cardiology/American Heart Association guidelines.E1 The maximal AA
diameter was measured preoperatively on a CT scan, angiocardiogram,
or echocardiogram and intraoperatively by direct measurement. The
diameters were seldom measured or recorded when they were perceived
to be normal (<40 mm).
Strategy for AA Management
Our decision-making process for AA management was, in principle,
guided, but not strictly limited, by the fixed guidelineE1 threshold AA
diameter of 45 mm. Other factors that influenced the decision were the
body surface area (BSA) and the age-related upper 2 standard deviation
limit of the normal AA diameter, leading to lower individualized and
variable thresholds.12 Additional parameters such as the perceived strength
of the AA wall (fragility and thickness), which was judged during
aortotomy for valve surgery, played a role. A progressive increase of the
AA diameter (>0.5 cm/y) and family history were also integrated into the
decision-making process, as appropriate. However, these factors seldom
occurred. Intervention on the AA was performed as AAR or AoP. The
parameters in favor of AAR were a larger diameter and/or tubular
configuration of the dilation, especially if the aortic arch was involved
(Fazel cluster III and IV13), younger age, the perceived fragility of the
wall tissue, rarely, a significant increase in the diameter of>0.5 cm in the
previous year, and a positive family history. The fragility of the wall tissue
was assumed when (1) placement of the cannulation sutures and snaring
tourniquets for cannula fixation caused bleeding and/or hematoma around
the cannulation site; (2) stay sutures above the commissures showed
unusual tearing through the wall; (3) aortotomy revealed thinning of the
wall; and/or (4) a pale vasa vasorum free area was present in the AAwall.
Parameters favoring AoP included eccentric, borderline dilatation confined
to the lateral AAwall (Fazel cluster II13), a normal appearing quality of the
AA wall, older age, no positive family history, and no significant
progression of the AA diameter, documented from previous examinations.
Parameters favoring no intervention included a smaller diameter, older age,
a high surgical risk, and severe comorbidities (Figure 2). Thus, the
decision to intervene was a combination of quantitative and qualitative
multifactorial, individualized parameters. Furthermore, the final decision
was also influenced by surgeon preference.Surgical Technique
Standard cardiopulmonary bypass with cannulation of the aortic
arch was used at hypothermia of 28C to 30C nasopharyngeal
temperature in all patients. Dacron grafts (DuPont, Wilmington, Del),
size 28 to 32, were used for AAR, relative to the patient’s size. The
distal and proximal suture lines were reinforced with a strip of Teflon felt
(DuPont). In the case of hemiarch replacement, cardiopulmonary arrest at
18C was applied for 20 minutes; thereafter, antegrade cerebral perfusion
was initiated.AoPwas performed as a plication of thewall between 2 Teflon
felts (Figure E1). The proximal part of the AoP was performed during
clamping of the AA and the distal third after declamping and de-airing.
Statistical Analysis
Descriptive variables are presented as the mean  standard deviation
and categorical variables as absolute and relative frequencies. The P values
of 2-sided tests are reported. For comparisons of the descriptive
characteristics, simple statistical tests (t test, chi-square test, analysis of
variance, Wilcoxon-Mann-Whitney test) were used as appropriate.diovascular Surgery c Volume 148, Number 5 2073
TABLE 1. Demographic and pre- and intraoperative clinical data (n ¼ 1362)
Variable Total (n ¼ 1362) BAV type 0 (n ¼ 115) BAV type 1 (n ¼ 1078) BAV type 2 (n ¼ 169) P value
BAV subtype —
ap, LR, LR/RN — ap 48 (41.7) LR 888 (82.4) LR/RN 153 (90.5)
lat, NL, LR/NL — lat 58 (50.4) NL 22 (2.0) LR/NL 6 (3.6)
RN, RN/NL — — RN 166 (15.4) RN/NL 6 (3.6)
Age (y) 56.6  14.9 54.2  13.4 58.8  14.3 44.7  13.4 *,y,z
BSA (m2) 1.98  0.21 1.97  0.21 1.98  0.21 1.97  0.2 NS
Male gender 1044 (76.7) 87 (75.7) 833 (77.3) 124 (73.4) NS
Hypertension 907 (66.6) 69 (60) 754 (69.9) 84 (49.7)
LVEF (%)
<30 37 (2.7) 0 (0) 34 (3.2) 3 (1.8)
30-50 195 (14.3) 13 (11.3) 166 (15.4) 16 (9.5)
>50 1054 (77.4) 95 (82.6) 811 (75.2) 148 (87.6)
Unknown 76 (5.6) 7 (6.1) 67 (6.2) 2 (1.2)
NYHA
I 332 (24.4) 25 (21.7) 260 (24.1) 47 (27.8)
II 486 (35.7) 44 (38.3) 367 (34) 75 (44.4)
III 412 (30.2) 38 (33) 329 (30.5) 45 (26.6)
IV 43 (3.2) 0 (0) 41 (3.8) 1 (0.6)
Unknown 89 (6.5) 7 (6.1) 81 (7.5) 1 (0.6)
Diabetes 162 (11.9) 9 (7.8) 147 (13.6) 6 (3.6)
COPD 104 (7.6) 4 (3.5) 92 (8.5) 8 (4.7)
AA procedure
No intervention 906 (66.5) 78 (67.8) 741 (68.7) 87 (51.5) z,x
Intervention
AAR 284 (20.9) 25 (21.7) 196 (18.2) 63 (37.3) z,x
Circulatory arrest (hemiarch) 158 (11.6) 10 (8.7) 107 (9.9) 41 (24.3) z,x
AoP 172 (12.6) 12 (10.4) 141 (13.1) 19 (11.2)
AA diameter (mm) 43.0  9.3 (n ¼ 974) 41.9  8.5 (n ¼ 78) 42.9  9.5 (n ¼ 741) 43.9  8.8 (n ¼ 155) NS
Aortic valve lesion
Stenosis 614 (45.1) 64 (55.7) 482 (44.7) 68 (40.2)
Insufficiency 268 (19.7) 24 (20.9) 240 (22.3) 4 (2.4)
Combined 480 (35.2) 27 (23.5) 356 (33) 97 (57.4)
Aortic valve procedure
Repair 142 (10.4) 16 (13.9) 122 (11.3) 4 (2.4)
Ross 337 (24.7) 19 (16.5) 217 (20.1) 101 (59.8)
Biologic valve 620 (45.5) 40 (34.8) 540 (50.1) 40 (23.7)
Mechanical valve 263 (19.3) 40 (34.8) 199 (18.5) 24 (14.2)
Bypass time (min) 152.1  63.2 135.5  59 146.4  61.1 194.9  60.5
Crossclamp time (min) 124.1  56.1 109.6  51.1 118.7  53.8 163.5  55.6
Mitral valve surgery 49 (3.6) 4 (3.5) 40 (3.7) 5 (3)
Tricuspid valve surgery 8 (0.6) 1 (0.9) 6 (0.6) 1 (0.6)
CABG 244 (17.9) 14 (12.2) 222 (20.6) 8 (4.7)
Root reconstruction 80 (5.9) 9 (7.8) 58 (5.4) 13 (7.7)
Bentall 65 (4.8) 6 (5.2) 51 (4.7) 8 (4.7)
David 37 (2.7) 5 (4.3) 31 (2.9) 1 (0.6)
Yacoub 11 (0.8) 1 (0.9) 10 (0.9) 0 (0)
Data presented as n (%) or mean  standard deviation. BAV, Bicuspid aortic valve; ap, anteroposterior; LR, raphe between left coronary and right coronary sinuses; RN, raphe
between right coronary and noncoronary sinuses; lat, lateral; NL, raphe between noncoronary and left coronary sinuses; BSA, body surface area; LVEF, left ventricular
ejection fraction; NYHA, New York Heart Association (functional classification); COPD, chronic obstructive pulmonary disease; AA, ascending aorta; AAR, AA replacement;
AoP, aortoplasty; CABG, coronary artery bypass grafting. *Type 0 versus type 1, P<.01. yType 0 versus type 2, P<.001. zType 1 versus type 2, P<.001. xType 0 versus
type 2, P<.01.
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(Kaplan-Meier, Cox proportional odds). The late postoperative survival
of the population and subgroups was compared to the survival expected
from the age- and gender-adjusted general population (available at:
www.destatis.de).142074 The Journal of Thoracic and Cardiovascular SurBinary and multinomial logistic regression analysis was used to
investigate the factors that influenced the decision to perform an interven-
tion on the AA (AAR or AoP). The following factors were investigated: AA
diameter, available for 975 patients (96.3% of the interventions), age, BAV
phenotype, and BSA. The AA size was forced into all models, andgery c November 2014
FIGURE 1. Schematic presentation of the classification system of the most frequent bicuspid aortic valve (BAV) phenotypes according to (A1) the number
of raphes or fusions and (A2) the spatial position of the commissures for type 0 and the raphes for types 1 and 2/unicuspid as viewed by the surgeon on the
right side of the patient. B, The spatial orientation of the characteristic of a BAV, with the fish mouth-like bifoliate valve opening shown. C, The develop-
mental state of the commissures. Thick line in the circle, Raphe; small circles, coronary ostia; shaded, valve opening area; L, left; R, right; ap, anteropos-
terior; lat, lateral; N, noncoronary; LR, raphe between left coronary and right coronary sinuses; RN, raphe between right coronary and noncoronary sinuses.
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investigated.
Recursive partitioning using conditional inferences trees15 was used
to investigate our AA decision process, how the effect of input variables
(AA diameter, age, BSA, BAV type) influenced this decision process,
and the resulting patterns of AA intervention. Bonferroni-adjusted P values
are presented in the decision tree.
Statistical analyses were performed using R, version 3.0.2 (R Develop-
ment Core Team, 2013; R: A language and environment for statistical
computing; R Foundation for Statistical Computing, Vienna, Austria;
available at www.R-project.org). The P values from the 2-sided tests are
reported.RESULTS
Mortality and Morbidity
The differences in the hospital mortality and morbidity
were not statistically significant between the treatment
groups (Table E2). Late survival was also not significantly
different statistically for the treatment groups and BAV
phenotypes. The life expectancy was comparable to that
of to the general German population (Figure E2). The cause
of late death is listed in Table E3, and no statistically signif-
icant difference between the treatment groups was
observed.The Journal of Thoracic and CarReoperation
For the purposes of the present study, we have reported
reoperations only on the AA. Reoperations on other cardiac
structures or for other indications have not been reported.
In the no intervention group, 4 reoperations were performed:
1 for type A acute dissection 12 years after the primary
operation,with anAAdiameter of 43mmat the primary oper-
ation; 1 for a false aneurysm at the site of aortotomy 1 year
postoperatively; 1 for endocarditis of a bioprosthesis concom-
itant with an aneurysm of the AA of 50 mm that had
developed within 2 years from 43 mm at the primary opera-
tion; 1 for endocarditis of a bioprosthesis and concomitant
dilatation of the AA of 45 mm. In the AoP group, 1 reopera-
tion was necessary because of infection of the prosthetic
material. In the AAR group, no reoperations occurred.
Freedom from reoperation was not different between the
BAV phenotypes or treatment strategies (Figure E2).
Freedom from reoperation at 10 years for those with BAV
type 0 was 93.9%, BAV type 1 was 95.3%, and BAV
type 2/unicuspid was 97.5% (P ¼ .7). Freedom from
reoperation at 10 years for the nontreatment group, AAR
group, and AoP group was 94.5%, 97.6%, and 96.1%,
respectively (P ¼ .5).diovascular Surgery c Volume 148, Number 5 2075
FIGURE 2. The probability (y-axis) that a patient will belong to 1 of the
ascending aorta (AA) groups (no intervention, aortoplasty [AoP], AA
replacement [AAR]), given a certain preoperative AA diameter (x-axis).
For example, at an AA diameter of 40 mm, the probability for a patient to
undergo AA intervention (AoP or AAR) was 0.25. In contrast, at an AA
diameter of 45 mm, the probability of AA intervention increased to 0.57.
Even at smaller diameters, intervention (AAR or AoP) was performed,
indicating that not only the diameter was decisive in decision making, but
also the other parameters, for a multifactorial individualized approach.
BSA, Body surface area; F, Fazel13; BAV, bicuspid aortic valve.
FIGURE 3. Probability of ascending aorta replacement in relation to
bicuspid aortic valve (BAV) phenotype. Patients with BAV type 2/unicuspid
underwent interventions significantly more often at a certain diameter than
did those with BAV type 1.
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The diameters and demographics stratified by the
AA management group are listed in Table E4. Figure 2
(conditional density plot) displays the probability (y-axis)
that a patient would belong to 1 of the groups (no interven-
tion, AoP, or AAR), given a certain preoperative AA
diameter (x-axis). For example, at an AA diameter of
40 mm, the probability for a patient to receive AA interven-
tion (AoP or AAR) was 0.25 and at a diameter of 43.9 mm
was 50%. The threshold AA diameter for intervention
(AoP or AAR) was not fixed but varied from 34 to 51 mm
(mean, 43.9) in relation to the outlined parameters.Management of AA and BAV Phenotype
Significantly more AARs were performed in patients
with BAV type 2/unicuspid than in those with BAV type
0 and 1 (Table 1). The probability of AAR with respect to
a certain diameter was significantly greater for those with
BAV type 2/unicuspid (Figure 3). When analyzing the 3
treatment modalities, patients with BAV type 1 LR (raphe
between left coronary and right coronary sinuses) and valve
insufficiency underwent AAR significantly more often
(Table E1). Also, significantly more root interventions
(Bentall, David, Yacoub, reconstruction) were performed
in those with BAV type 1 LR with an insufficient valve2076 The Journal of Thoracic and Cardiovascular Surlesion than in those with BAV type 1 LR with a combined
or stenotic valve lesion (36% vs 11% vs 5%, respectively;
P< .001). A decision tree displaying the variables that
exhibited a statistically significant influence in the patient
therapy selection process for the population of the present
study is shown in Figure 4.
AA and BAV Phenotypes
In 583 patients (54% of the total) with BAV type 1, data
on the AA pattern according to the Fazel classification13
were available. For BAV type 1 LR and BAV type 1 RN
(raphe between right coronary and noncoronary sinuses),
a normal configuration was found in 144 and 29, cluster I
in 24 and 5, cluster II in 223 and 28, cluster III in 19 and
8, and cluster IV in 84 and 19, respectively. Cluster II was
more frequent in those with BAV type 1 LR than in those
with BAV type 1 RN (P<.05).
DISCUSSION
The results of the present study have provided some
evidence that 14 years postoperatively, an individualized
multifactorial strategy for treatment of the AA during
BAV surgery will lead to excellent results, with low hospital
morbidity and mortality, a low rate of reoperation, and
survival comparable that of to the general population. The
phenotypes BAV type 2/unicuspid and BAV type 1 with
insufficiency were found to be new determinants for more
aggressive AAR.
Intervention on the AA using AoP or AAR has the aim of
preventing later rupture or dissection. This risk is greater ingery c November 2014
FIGURE 4. Graphic depiction of the decision tree investigating our ascending aorta (AA) management process, the effect of the preoperative variables
(AA diameter, body surface area [BSA], bicuspid aortic valve [BAV] type), and the resulting patterns of AA intervention. AAR, AA replacement;
AoP, aortopathy.
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present for the whole life expectancy, which can extend to
50 years or even more after the initial operation. The
risk also increases owing to aging-related progressive
AA dilatation and degeneration.16,17 These facts must be
considered and weighed against the surgical risk during
the decision-making process of when and how to treat the
AA and also when interpreting data from follow-up studies,
which have rarely exceeded 10 to 15 years of follow-up.
Determining When to Operate on the AA
Wall tension is the major determinant of the tear-ability
or risk of rupture of the AA. According to the law of
Laplace, the wall tension includes the AA diameter multi-
plied by the blood pressure divided by the wall strength.
Physiologically, theAA is outgrown in relation to theBSA
after adolescence.However, it still increases in diameterwith
age16 and in association with AA tissue degeneration,17 both
enhancing the risk of rupture or dissection. This risk is
considerable at a diameter of 5.5 cm.18 The current
guidelinesE1 have recommend surgery on the AA in patients
with a diameter of>4.5 cm without age- and BSA-related
differentiation. However, the question remain regarding
how we should treat a young patient with a borderline
diameter of the AA at valve surgery, a diameter that with
aging-related dilatation and degeneration during the
patient’s long life expectancywill increase to the cutoff value
or morewithin some years after surgery, keeping in mind the
increased risk of rupture in patients with BAV.2-4
Considering these facts, we believe that in addition to theThe Journal of Thoracic and CarAA diameter, at the least, the patient’s age and BSA should
be included in the decision-making process for every patient.
Hypertension, the second factor, should be thoroughly
kept in mind and treated aggressively, although increases
in blood pressure owing to emotional stress and different
situations have been difficult to capture. Furthermore,
medical therapy for blood pressure control and limitation
of AA dilation can play a crucial role in the fate of the
AA and should be considered in future studies.
The third factor is wall strength. When the AA is
transected for valve replacement, visual examination by
an experienced surgeon can provide some impression of
the strength of the AAwall, defined as fragility or thinning
of the tissue, which was recently published for surgery of
type A dissection.19 However, the subjectivity of this
qualitative criterion is great and requires additional
objectivization. Whether the different shapes of the AA
according to Fazel and colleagues13 will correlate with
the perceived tissue quality remains to be evaluated.
Furthermore, genetics and hemodynamics could be
potential factors causing tissue weakness. Some evidence
has shown that the genetic defects causing the BAV
pathologic features could also have an effect on the tissue
of the AA.7 Hemodynamic shear stress has also been
reported to accelerate AA dilatation.9 Both hemodynamic
and genetic reasons could be related to the BAV phenotype.
Thus, we found that patients with BAV type 2/unicuspid
underwent AAR significantly more often, independent of
the AA diameter (Figure 3). Thus, roughly 50% of patients
with BAV type 2/unicuspid had undergone AAR at adiovascular Surgery c Volume 148, Number 5 2077
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stratified according to the preoperative hemodynamics,
patients with BAV type 1 LR with valve insufficiency
had undergone AAR more often than no intervention
(Table E1). This fits with the findings from Roberts and
colleagues,20 who reported that patients with regurgitant
BAVs had more pronounced pathologic features of the
AA wall. This was supported by the finding that
significantly more root interventions were performed in
the BAV type 1 LR group with an insufficient valve than
in the BAV type 1 LR group with combined or stenotic valve
lesions. In a recent study, Thanassoulis and colleaguesE4
showed that those with BAV type 1 LR and moderate to
severe regurgitation were more likely to have a dilated
aorta, confirming our results. Whether these BAV types
reflect a more severe form of genetic abnormality and
a more malignant form of aortopathy is unknown.
Nevertheless, the present study has provided some evidence
that BAV type 2/unicuspid and BAV type 1 with valve
insufficiency could be determinants for more aggressive
AAR in our practice. Furthermore, patients who underwent
root surgery had a significantly larger AA diameter than
those who id not undergo root surgery (54 vs 49 mm,
P < .001), possibly indicating a more severe form of
aortopathy in these patients.
Significantly more patients with BAV type 1 LR had a
cluster II pattern with regional AA dilatation along the
convexity than did those with BAV type 1 RN, indicating
that the valve phenotypes might be associated with different
AA configurations, probably related in part to different flow
and shear stress characteristics.E2 These findings were also
reflected by the differences in the matrix metalloproteinases
and endogenous tissue inhibitors.E3
Taking together, the results of the present study have
shown that more factors might be influencing the decision
making than just the diameter (Figure 2). Figure 4 shows
the relatively simple decision tree from our data that only
included the AA diameter, BSA, and BAV type. Other
determinants, such as family history, growth progression,
and tissue strength, were not included, because they
occurred too seldom or were qualitative.
Operating on AA Dilatation—AAR or AoP?
Although AAR seems theoretically to be the safest
solution to treat AA dilatation, it has its own risks—first,
increased operative mortality and morbidity owing to the
longer operative time. In our study, the hospital mortality,
including after valve surgery, was not increased in the
AAR group, although AAR was accompanied by the
greatest rate of hemiarch surgery with circulatory arrest,
indicating that this surgical risk might be negligible in
experienced centers. Second, the nonelasticity of the
Dacron tube graft causes a loss of the Windkessel function,
with the potential for aortic root aneurysm, left ventricular2078 The Journal of Thoracic and Cardiovascular Surhypertrophy, late cardiac mortality, increased wall tension
of the remaining aorta and, thus, potentially, type B
dissection, annulus dilatation, valve dysfunction, and
exercise impairment.21-24 In our study, we did not detect
these adverse events; however, the follow-up period was
too short for a final judgment, and we did not investigate
all of these items. Because of these potential shortcomings,
we used AAR mainly in patients with larger AA diameters
(Table E4).
In contrast to AAR, AoP preserves the Windkessel
function.25 The results of AoP have been reported to be
satisfactory, safe, and durable if the diameter can be
adequately reduced to about 3.6 cm.26 It should be performed
in patients with borderline dilatation27 (Table E4, Figure 2)
and not in patients with an insufficient valve28; AoP can
also be performed in those with post-stenotic AA dilatation
and in elderly patients.29 We followed this policy and
performed AoP at the convexity of the AA, the portion
probably most affected by histologic abnormalities.30 To
date, the results from our study have supported this strategy;
only 1 reoperation was necessary in the AoP group owing to
infection of the prosthetic material. Nevertheless, a potential
risk exists for later dilation and reoperation, leaving the appli-
cation of AoP controversial and largely determined by sur-
geon preference until we have more reliable long-term data.
Our individualized policy for treatment of the AA during
BAV surgery led to amore aggressive approach, with 33.5%
of patients undergoing an intervention, compared with a
recently published incidence of 20%.31 Our results reflect
the observed trend of an increased incidence of thoracic
aorta surgery in patients with BAV.32 We believe the known
increased risk of AA complications in patients with BAV,2-4
the age-related increase in AA diameter with tissue degen-
eration, and that smaller size AAs can rupture (40% of acute
type A dissections occurred at AA diameters of<50 mm in
the International Registry of Acute Aortic Dissection trial33)
justify and support an individualized multifactorial, more
aggressive AA approach, especially for those with BAV
type 2/unicuspid and BAV type 1 with regurgitation during
valve surgery. Four reoperations on the AAwere performed
in the no intervention group during the follow-up period.
Whether this finding is a hint to be even more aggressive
remains to be seen after longer follow-up periods. Our
policy has been supported by the report from Russo and
colleagues,34 advocating a more prophylactic replacement
approach, and, most recently, by the report from Stanger
and colleagues,19 emphasizing a potentially lower threshold
for prophylactic replacement of the AA in experienced
centers, particularly in patients with aortic regurgitation,
hypertension, and thinning of the aortic wall.
The Future
The development of prostheses with durable flexibility
that preserve the Windkessel function over time couldgery c November 2014
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commonly used unelastic Dacron prostheses and thus might
lower the threshold for AAR. The development of a histo-
logic quick test could also be helpful in decision making.
Our study reports on a cautious beginning of an
individualized differentiated strategy. For more sophisti-
cated risk calculation2 and, thus, a meaningful individual-
ized decision tree weighing the risks and benefits, we
need additional, ideally lifelong, information on these
factors, genes, biomarkers, other genetically related
parameters, and environmental data (eg, hypertension,
sheer stress, turbulence) to determine the fate of the AA.
We also require follow-up data on procedure-related
outcomes. We agree with the views of Fedak and VermaE5
that ‘‘the current guidelines for aortic resection and patients
with aortopathy are too simple’’ and ‘‘personally tailored
approaches for the patients with bicuspid aortic syndrome
are crucial because the disease is clinically heterogeneous,
making individual predictions particularly challenging.’’
This goal, however, requires acquisition of a large amount
of data.2 An encouraging proposal for more effective data
collection on a larger, or even global, scale was recently
reported by Moody.35
Study Limitations and Strengths
Measurement of the AA diameter was performed using
several techniques, just as is usually the case in clinical
practice. Thus, differences in these measurement methods
could have led to measurement-related differences in the
AA diameter. The differences in the measurement methods
were also a reason to not rely on the diameter alone, but to
include other parameters for the decision regarding AA
treatment. Furthermore, we would have preferred to obtain
>59% of AA diameter measurements in the no intervention
group; however, for many of these patients, AA diameters
that seemed normal were not measured but only described
as ‘‘normal.’’
The mean follow-up period was relatively short at 5.4
years, and only 14% of patients (n ¼ 189) were followed
up for>10 years. Thus, the implications are limited, and
longer follow-up periods are necessary to consolidate our
management policy.
The development of the AA diameter postoperatively,
especially in the no intervention and AoP groups, would
be of great interest, because it is possible that some AAs
might have become dilated. This would indicate the
potential for a change in the protocol in favor of more
frequent AAR. This will be evaluated in future research.
In a recent publication,8 we could not find a progressive
increase in the AA diameter after correction of pathologic
hemodynamics using a Ross procedure compared with
normal individuals. Also, we could not demonstrate
whether any type of intervention or no intervention was
the best treatment modality, we could only present ourThe Journal of Thoracic and Carresults and our protocol. To consolidate our results, more
information will be necessary. One advantage of the present
study was its design concerning the integration of individual
parameters for decision making as an encouraging, and
theoretically reasonable, concept. Another advantage was
the relatively large number of BAV phenotypes.
We would like to thank Michael Diwoky and Tobias Frin for
their excellent data management and analyses and their assistance
in preparing our report for publication.References
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strategiesPaul W. M. Fedak, MD, PhD, FRCSC,a,b and Subodh Verma, MD, PhD, FRCSCc,dIn an effort to better understand current surgical approaches,
we compared the knowledge and attitudes of individual sur-
geons toward the diagnosis and management of bicuspid
aortopathy.1 Surprisingly, surgeons’ approaches often went
outside established guidelines, with marked differences inthe timing, extent, and type of operative strategy of aortic
resection. Bicuspid aortopathy is a commonly encountered
clinical scenario, so why are surgeons so disparate and non-
compliant with current recommendations? We believe that
the heterogeneous nature of the disease and its diverse clin-
ical phenotypes2 may influence a surgeon’s threshold for
aortic replacement, despite current guidelines. Unfortu-
nately, there are no consensus recommendations on the
type or extent of aortic repair for an individual patient
with bicuspid aortopathy, and no randomized clinical trials
are available to better inform clinicians as to whether an
aggressive versus conservative approach is appropriate.
Although arm-deep in a patient’s chest and inspired by the
best intentions, surgeons might avoid the recommendations
in selected patients and recognize that contemporary guide-
lines for aortic resection in patients with bicuspid aortic
valve based solely on maximal aortic diameter are deficient
and lack an appreciation for the numerous factors that may
underlie disease progression.
To achieve optimal clinical outcomes for bicuspid
aortopathy, individualized surgical approaches for patients
with bicuspid aortic valve disease may be a necessity. In
their report in this issue of the Journal, Sievers andgery c November 2014
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FIGUREE1. Schematic presentation of the surgical technique for aortop-
athy. The eccentric part of the ascending aorta is plicated between 2 Teflon
felts using a mattress and over and over continuous suture.
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FIGURE E2. Survival (upper graphs) and freedom from reoperation (lower graphs) in relation to (A) bicuspid aortic valve (BAV) phenotypes and
(B) management of ascending aorta. n.s., Not significant.
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TABLE E1. BAV phenotypes and hemodynamics stratified by AA
management
BAV type Total
No
intervention AoP AAR
P
value
Type 0, ap 48 (100) 37 (100) 2 (100) 9 (100) NC
Insufficiency 12 (25) 11 (29.7) 0 (0) 1 (11.1)
Stenosis 24 (50) 19 (51.4) 0 (0) 5 (55.6)
Combined 12 (25) 7 (18.9) 2 (100) 3 (33.3)
Type 0, lat 58 (100) 34 (100) 9 (100) 15 (100) NC
Insufficiency 12 (20.7) 6 (17.6) 1 (11.1) 5 (33.3)
Stenosis 33 (56.9) 23 (67.6) 6 (66.7) 4 (26.7)
Combined 13 (22.4) 5 (14.7) 2 (22.2) 6 (40)
Type 1, LR 888 (100) 603 (100) 118 (100) 167 (100)
Insufficiency 202 (22.7) 117 (19.4) 27 (22.9) 58 (34.7) *,y
Stenosis 390 (43.9) 291 (48.3) 48 (40.7) 51 (30.5) *
Combined 296 (33.3) 195 (32.3) 43 (36.4) 58 (34.7) NS
Type 1, NL 22 (100) 19 (100) 2 (100) 1 (100) NC
Insufficiency 6 (27.3) 5 (26.3) 0 (0) 1 (100)
Stenosis 11 (50) 10 (52.6) 1 (50) 0 (0)
Combined 5 (22.7) 4 (21.1) 1 (50) 0 (0)
Type 1, RN 166 (100) 119 (100) 19 (100) 28 (100) NC
Insufficiency 32 (19.3) 22 (18.5) 3 (15.8) 7 (25)
Stenosis 79 (47.6) 66 (55.5) 8 (42.1) 5 (17.9)
Combined 55 (33.1) 31 (26.1) 8 (42.1) 16 (57.1)
Type 2, LR/RN/
unicuspid
153 (100) 77 (100) 17 (100) 59 (100) NC
Insufficiency 4 (2.6) 1 (1.3) 0 (0) 3 (5.1)
Stenosis 62 (40.5) 37 (48.1) 5 (29.4) 20 (33.9)
Combined 87 (56.9) 39 (50.6) 12 (70.6) 36 (61)
Data presented as n (%). BAV, Bicuspid aortic valve; AA, ascending aorta;
AoP, aortopathy; AAR, AA replacement; ap, anteroposterior; NC, not calculated
(number of patients too small); lat, lateral; LR, raphe between left coronary and right
coronary sinuses; NS, not significant; NL, raphe between noncoronary and left
coronary sinuses; RN, raphe between right coronary and noncoronary sinuses.
*No intervention versus AAR, P<.001. yAAR versus AoP, P<.05.
TABLE E2. Postoperative outcomes (30 d) stratified by AA
management
Outcome
Total
(n ¼ 1362)
No intervention
(n ¼ 906)
AoP
(n ¼ 172)
AAR
(n ¼ 284)
Hospital mortality 12 (0.9) 10 (1.1) 1 (0.6) 1 (0.4)
IABP 22 (1.6) 18 (2.0) 1 (0.6) 3 (1.1)
Reoperation for
bleeding
66 (4.8) 39 (4.3) 7 (4.1) 20 (7.0)
Permanent
stroke>72 h
5 (0.4) 4 (0.4) 1 (0.6) 0 (0)
Dialysis 40 (2.9) 32 (3.5) 5 (2.9) 3 (1.1)
Data presented as n (%). AA, Ascending aorta; AoP, aortopathy; AAR, AA replace-
ment; IABP, intra-aortic balloon pump.
TABLE E4. AA diameter, age, BSA, and gender stratified by AA
management
Variable No intervention AoP AAR
P
value
Total 906 (100) 172 (100) 284 (100)
Patients with
measured diameter
535 (59.1) 162 (94.2) 277 (97.5)
Diameter (mm) *,y,z
Mean  SD 36.7  5.1 46.5  4.9 53.1  7.3
Median 37 46 52
Range 22-51 35-65 34-84
Age (y) 54.1  15.0 57.3  14.3 52.5  12.9 z,x
BSA (m2) 1.98  0.20 1.98  0.21 2.01  0.22 jj
Male gender 425 (79.4) 118 (72.8) 219 (79.1) NS
Data presented as n (%) or mean SD, unless otherwise noted. AA, Ascending aorta;
BSA, body surface area; AoP, aortopathy; AAR, AA replacement; SD, standard devi-
ation; NS, not significant. *No intervention versus AAR, P<.001. yNo intervention
versus AoP, P< .001. zAAR versus AoP, P< .001. xNo intervention versus AoP,
P<.05. jjNo intervention versus AAR, P<.01.
TABLE E3. Cause of late death (>30 d) stratified by AA management
Variable
Total
(n ¼ 1362)
No intervention
(n ¼ 906)
AoP
(n ¼ 172)
AAR
(n ¼ 284)
Cause of late death
Cardiac 29 (2.1) 24 (2.6) 3 (1.7) 2 (0.7)
Noncardiac 72 (5.3) 52 (5.7) 11 (6.4) 9 (3.2)
Unknown 17 (1.2) 12 (1.3) 4 (2.3) 1 (0.4)
LOR (%/pt-y) 0.40 0.49 0.30 0.14
Data presented as n (%). AA, Ascending aorta; AoP, aortopathy; AAR, AA replace-
ment; LOR, linearized occurrence rate; pt-y, patient-year.
Acquired Cardiovascular Disease Sievers et al
2080.e3 The Journal of Thoracic and Cardiovascular Surgery c November 2014
A
C
D
